pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,414 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1020Endpoints770BioPharma Dive293BioSpace210Fierce Biotech198onclive165raps74globenewswire health
therapy area
allOncology5950Rare Disease1405Cardiology1087Hematology1011Immunology991Pulmonology892Vaccines
  • Boston ER doctor Jeremy Faust grows influence with Inside Medicine newsletter
    Jeremy Faust works as an emergency physician at Brigham and Women's Hospital in Boston, handling busy shifts and caring for dozens of patients. In addition to his clinical duties, Faust runs the S…
    STAT · 1mo agoPositive↗ source
  • Boys' Club of New York offers after-school program that supports mental health of at-risk boys
    The Boys' Club of New York, a 150-year-old organization, runs three clubhouses serving about 2,500 middle-school boys from disadvantaged backgrounds. The program provides after-school and weekend…
    STAT · 1mo agoPositive↗ source
← prev
page 25 of 57
next →
73
fda recalls47
fda medwatch36
fda press28
885
Psychiatry & CNS710
Ophthalmology419
Endocrinology & Metabolism377
Pain371
Infectious Disease346
GSK ends $2.2 billion brain drug partnership with Alector after trial failures
GSK and California‑based biotech Alector have ended their collaboration after both experimental brain drugs failed to meet development milestones. The partnership, announced in July 2021, gave GSK…
BioPharma Dive · 1mo agoDealNegative↗ source
  • Michigan sees nearly 1,000 cyclospora cases, the state's largest outbreak and among the nation's biggest
    Nearly a thousand residents of Michigan have been diagnosed with a cyclospora infection that causes prolonged watery diarrhea, making it the biggest outbreak in the state's history and one of the l…
    STAT · 1mo agoNeutral↗ source
  • ARPA-H launches $160 million THRIVE program to fund seven labs developing custom gene-editing therapies for rare diseases
    ARPA-H, the U.S. Advanced Research Projects Agency for Health, announced a new initiative called THRIVE with up to $160 million in funding. The program will support seven research teams over five…
    STAT · 1mo agoPositive↗ source
  • Prime Secures Arbitration Victory Over Beam, Paving Way for Clinical Trials
    Prime, a biotech firm developing a gene‑therapy candidate, won an arbitration case against Beam Therapeutics. The ruling removes a legal hurdle and allows Prime to advance its program into clinical…
    STAT · 1mo agoRegulatoryPositive↗ source
  • AstraZeneca/Ionis heart-failure drug Wainua fails pivotal trial as White House reviews FDA commissioner candidates
    The White House is reviewing a shortlist of three candidates for the FDA commissioner position, according to STAT. The list includes White House adviser Heidi Overton, oncologist and health‑system…
    STAT · 1mo agoNegative readoutNegative↗ source
  • New OpenEvidence study shows it outperforms general-purpose LLMs in health-tech research
    A recent study funded by OpenEvidence compared its platform to general-purpose large language models (LLMs) in health technology research and concluded that OpenEvidence delivered more accurate and…
    STAT · 1mo agoPositive↗ source
  • Roche scraps two Ionis-partnered Huntington’s drugs
    The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.
    BioPharma Dive · 1mo agoRegulatoryNeutral↗ source
  • White House reviews three candidates to lead the FDA
    STAT+ reports that the White House is currently evaluating three leading candidates to become the next head of the Food and Drug Administration. The review process is part of the administration's e…
    STAT · 1mo agoRegulatoryNeutral↗ source
  • Podcast discusses health insurance costs, whistleblower case, and potential FDA commissioner picks
    The Readout LOUD podcast episode explores why employer-provided family health insurance can be as expensive as a new car. The hosts interview a whistleblower who challenged an insurance contractor…
    STAT · 1mo agoRegulatoryNeutral↗ source
  • HHS plan to speed drug research won’t remove ‘self-inflicted’ delays
    U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?
    BioPharma Dive · 1mo ago↗ source
  • AstraZeneca, Ionis drug fails big heart disease study in major setback
    Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.
    BioPharma Dive · 1mo ago↗ source
  • Who’s going to run the FDA?
    RFK Jr.'s list of Covid vaccine injuries, a father's quest to cure his daughter, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • STAT+: 931 days. The drug approval scandal hiding in plain sight
    Two years, six months, and 18 days have elapsed since Northwest Biotherapeutics submitted its brain cancer treatment for regulatory approval.
    STAT · 1mo ago↗ source
  • STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
    AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drugmakers.
    STAT · 1mo ago↗ source
  • Opinion: Your grandparents are using cannabis. Doctors can help them do it safely
    Over the past 25 years, I have treated thousands of medical cannabis patients with extremely few ill effects, one doctor writes.
    STAT · 1mo ago↗ source
  • Opinion: Who benefits from classifying obesity as a disease?
    “The new wave of obesity pharmacotherapy has leaned heavily on disease framing,” writes Max Moser, drawing comparisons to the antidepressant revolution.
    STAT · 1mo ago↗ source
  • STAT+: The quest to save Grace — and clear the way for rare disease patients everywhere
    How a father’s quest may shape the future of rare disease gene therapy.
    STAT · 1mo ago↗ source
  • What happens on ‘MAHA Monday’?
    STAT's Alex Hogan and Chelsea Cirruzzo stopped by "MAHA Monday" at the Great American State Fair. Watch their report in this week's STATus Report.
    STAT · 1mo ago↗ source
  • STAT+: RFK Jr. plans to create list of injuries caused by Covid-19 vaccines
    It's not clear what conditions may make the list, but outside experts are watching it closely.
    STAT · 1mo ago↗ source
  • STAT+: White House reviewing top contenders to lead FDA
    The White House is reviewing finalists for FDA commissioner, suggesting the highly anticipated decision may come soon.
    STAT · 1mo ago↗ source
  • STAT+: Mass General Brigham, nurses called to talk at State House amid biggest nursing strike in Mass.
    The Brigham, a nationally renowned Harvard teaching hospital, and MGB have have unsuccessfully been negotiating a new contract for months.
    STAT · 1mo ago↗ source
  • STAT+: In private meeting, Trump officials push to onshore generic drugmaking
    Marco Rubio, RFK Jr., and Chris Klomp are urging industry leaders to make more medicines in the U.S.
    STAT · 1mo ago↗ source
  • Bryan Johnson’s chronic disease is notoriously difficult to diagnose
    Why longevity entrepreneur Bryan Johnson’s chronic disease is notoriously difficult to diagnose.
    STAT · 1mo ago↗ source